CMND-100 Trial Receives DSMB Approval to Advance, Increase Dose
CMND sits 36% above its 52-week low of $0.595 on elevated volume (37× avg).
Summary
Clearmind Medicine announced that its independent Data and Safety Monitoring Board (DSMB) has given a positive recommendation to continue the Phase I/IIa clinical trial for CMND-100, its drug candidate for Alcohol Use Disorder. This decision, based on encouraging top-line safety data from the third cohort, allows the company to proceed to the fourth cohort and increase the tested dose to 160mg. This news builds on yesterday's reports that CMND-100 met its primary safety and tolerability endpoint, with the DSMB's formal approval providing critical validation and a clear path forward. For a micro-cap biotech, this is a highly material de-risking event, confirming the drug's safety and tolerability and advancing it significantly through the development pipeline. Traders will now watch for updates on the fourth cohort, particularly regarding any early efficacy data at the higher dose.
At the time of this announcement, CMND was trading at $0.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9M. The 52-week trading range was $0.59 to $52.40. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.